Controversies for the recommendation of coenzyme Q10 supplements to mitigate statin-induced myalgia

Cardiovascular disease is the main cause of death in Spain, according to the National Institute of Statistics (INE). Statins reduce this risk, but their muscular adverse effects are, occasionally, a drawback to maintaining this treatment. In community pharmacies, the indication of coenzyme Q10 supplements to reverse this adverse effect is frequent, as it has been confirmed that statins lower its concentration as they do with cholesterol. However, the correlation between this supplement and the prevention of statin-induced myalgia is doubtful, given the disparity of clinical studies that assess this therapeutic strategy. It is necessary to obtain sound and reproducible clinical testing that evaluate this use of coenzyme Q10 to create confidence in its recommendation for this purpose or apply therapies backed with more solid evidence